Inozyme Pharma, Inc. Stock Position Raised by Affinity Asset Advisors LLC - MarketBeat
| ZBIO Etf | USD 11.75 0.32 2.80% |
About 54% of Zenas BioPharma,'s investors are presently thinking to get in. The analysis of overall sentiment of trading Zenas BioPharma, Common etf suggests that some investors are interested at this time. Zenas BioPharma,'s investing sentiment overview a quick insight into current market opportunities from investing in Zenas BioPharma, Common. Many technical investors use Zenas BioPharma, Common etf news signals to limit their universe of possible portfolio assets and to time the market correctly.
Zenas |
Inozyme Pharma, Inc. Stock Position Raised by Affinity Asset Advisors LLC MarketBeat
Read at news.google.com
 |
Zenas BioPharma, Fundamental Analysis
We analyze Zenas BioPharma,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zenas BioPharma, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zenas BioPharma, based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Zenas BioPharma, is rated second in total debt as compared to similar ETFs. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Zenas BioPharma, Common Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zenas BioPharma, etf to make a market-neutral strategy. Peer analysis of Zenas BioPharma, could also be used in its relative valuation, which is a method of valuing Zenas BioPharma, by comparing valuation metrics with similar companies.
Peers
Zenas BioPharma, Related Equities
| AMLX | Amylyx Pharmaceuticals | 5.32 | ||||
| GRI | GRI Bio | 4.11 | ||||
| ZBIO | Zenas BioPharma, | 2.80 | ||||
| Z | Zillow Group | 0.71 | ||||
| MBBB | VanEck Vectors | 0.23 | ||||
| ENGN | EnGene Holdings | 0.12 | ||||
| DHDG | FT Vest | 0.16 | ||||
| MBCC | Northern Lights | 0.31 | ||||
| PRME | Prime Medicine, | 1.20 |
Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.